Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Enalapril maleate
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Apo-Enalapril · DIN 02020025 · 2.5 mg · tablet
General benefitMarketed · checked November 19, 2026
Write on scriptno code needed
1 brand, same coverage
Apo-Enalapril · DIN 02020025
Manufacturer: Apotex Inc.; listing date 2007-12-19
Daily cost (source): $0.1863
Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Enalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02020025)
Source record
DIN 02020025: Apo-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id APX
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02020025
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14385
Interchangeable products
Co Enalapril · DIN 02291878 · $0.1863
Enalapril · DIN 02400650 · $0.1863
Enalapril · DIN 02442957 · $0.1863
Jamp-Enalapril · DIN 02474786 · $0.1863
Mar-Enalapril · DIN 02459450 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ran-Enalapril · DIN 02352230 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended March 5, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02020025
Shortage record checked October 6, 2026
Co Enalapril · DIN 02291878 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Co Enalapril · DIN 02291878
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19
Daily cost (source): $0.1863
Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 2 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Enalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02291878)
Source record
DIN 02291878: Co Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id COB
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02291878
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77724
Therapeutic Notes (formulary)
** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863
Enalapril · DIN 02400650 · $0.1863
Enalapril · DIN 02442957 · $0.1863
Jamp-Enalapril · DIN 02474786 · $0.1863
Mar-Enalapril · DIN 02459450 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ran-Enalapril · DIN 02352230 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended February 19, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02291878
Shortage record checked October 6, 2026
Enalapril · DIN 02400650 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Enalapril · DIN 02400650
Manufacturer: Sanis Health Inc.; listing date 2022-02-28
Daily cost (source): $0.1863
Health Canada: Marketed since 2022-01-07 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEnalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400650)
Source record
DIN 02400650: Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id SAI
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400650
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88543
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863
Co Enalapril · DIN 02291878 · $0.1863
Enalapril · DIN 02442957 · $0.1863
Jamp-Enalapril · DIN 02474786 · $0.1863
Mar-Enalapril · DIN 02459450 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ran-Enalapril · DIN 02352230 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended January 3, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400650
Shortage record checked October 6, 2026
Enalapril · DIN 02442957 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Enalapril · DIN 02442957
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30
Daily cost (source): $0.1863
Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 2 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEnalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442957)
Source record
DIN 02442957: Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id SIV
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442957
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92748
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863
Co Enalapril · DIN 02291878 · $0.1863
Enalapril · DIN 02400650 · $0.1863
Jamp-Enalapril · DIN 02474786 · $0.1863
Mar-Enalapril · DIN 02459450 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ran-Enalapril · DIN 02352230 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended March 25, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442957
Shortage record checked October 6, 2026
Jamp-Enalapril · DIN 02474786 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Jamp-Enalapril · DIN 02474786
Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30
Daily cost (source): $0.1863
Health Canada: Marketed since 2019-02-25 · brand JAMP ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Enalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474786)
Source record
DIN 02474786: Jamp-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id JPC
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474786
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96497
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863
Co Enalapril · DIN 02291878 · $0.1863
Enalapril · DIN 02400650 · $0.1863
Enalapril · DIN 02442957 · $0.1863
Mar-Enalapril · DIN 02459450 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ran-Enalapril · DIN 02352230 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended July 3, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474786
Shortage record checked October 6, 2026
Mar-Enalapril · DIN 02459450 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Mar-Enalapril · DIN 02459450
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28
Daily cost (source): $0.1863
Health Canada: Marketed since 2019-03-20 · brand MAR-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 2.5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Enalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02459450)
Source record
DIN 02459450: Mar-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id MAR
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02459450
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94669
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863
Co Enalapril · DIN 02291878 · $0.1863
Enalapril · DIN 02400650 · $0.1863
Enalapril · DIN 02442957 · $0.1863
Jamp-Enalapril · DIN 02474786 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ran-Enalapril · DIN 02352230 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02459450
Shortage record checked October 6, 2026
Ran-Enalapril · DIN 02352230 · 2.5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Ran-Enalapril · DIN 02352230
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-01-07
Daily cost (source): $0.1863
Health Canada: Marketed since 2022-02-15 · brand TARO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM 2 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Enalapril: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1863). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02352230)
Source record
DIN 02352230: Ran-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800149; group id 322; item number 0715; lccId None; manufacturer id RAN
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1863; ministry $0.1863
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352230
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83747
Interchangeable products
Apo-Enalapril · DIN 02020025 · $0.1863
Co Enalapril · DIN 02291878 · $0.1863
Enalapril · DIN 02400650 · $0.1863
Enalapril · DIN 02442957 · $0.1863
Jamp-Enalapril · DIN 02474786 · $0.1863
Mar-Enalapril · DIN 02459450 · $0.1863
Mylan-Enalapril · DIN 02300036 · $0.1863
Novo-Enalapril · DIN 02300680 · $0.1863
Ratio-Enalapril · DIN 02299984 · $0.1863
Sandoz Enalapril · DIN 02299933 · $0.1863
Taro-Enalapril · DIN 02300117 · $0.1863
Vasotec · DIN 00851795 · not recorded
Shortage status: resolved shortage (ended April 10, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352230
Shortage record checked October 6, 2026
Apo-Enalapril · DIN 02019884 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Enalapril · DIN 02019884
Manufacturer: Apotex Inc.; listing date 2007-12-19
Daily cost (source): $0.2203
Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Enalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02019884)
Source record
DIN 02019884: Apo-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02019884
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14386
Interchangeable products
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended November 7, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02019884
Shortage record checked October 6, 2026
Co Enalapril · DIN 02291886 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Enalapril · DIN 02291886
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19
Daily cost (source): $0.2203
Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 4 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Enalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02291886)
Source record
DIN 02291886: Co Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id COB
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02291886
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77725
Therapeutic Notes (formulary)
** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: discontinued (April 7, 2017, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02291886
Shortage record checked October 6, 2026
Enalapril · DIN 02400669 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Enalapril · DIN 02400669
Manufacturer: Sanis Health Inc.; listing date 2022-02-28
Daily cost (source): $0.2203
Health Canada: Marketed since 2022-01-07 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEnalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400669)
Source record
DIN 02400669: Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400669
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88544
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended January 7, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400669
Shortage record checked October 6, 2026
Enalapril · DIN 02442965 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Enalapril · DIN 02442965
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30
Daily cost (source): $0.2203
Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 4 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEnalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442965)
Source record
DIN 02442965: Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442965
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92749
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended October 19, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442965
Shortage record checked October 6, 2026
Jamp-Enalapril · DIN 02474794 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Enalapril · DIN 02474794
Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30
Daily cost (source): $0.2203
Health Canada: Marketed since 2019-02-25 · brand JAMP ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Enalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474794)
Source record
DIN 02474794: Jamp-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474794
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96498
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended April 15, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474794
Shortage record checked October 6, 2026
Mar-Enalapril · DIN 02459469 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Enalapril · DIN 02459469
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28
Daily cost (source): $0.2203
Health Canada: Marketed since 2019-03-20 · brand MAR-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 5 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Enalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02459469)
Source record
DIN 02459469: Mar-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id MAR
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02459469
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94670
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02459469
Shortage record checked October 6, 2026
Ran-Enalapril · DIN 02352249 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Enalapril · DIN 02352249
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-01-07
Daily cost (source): $0.2203
Health Canada: Marketed since 2022-02-15 · brand TARO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM 4 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Enalapril: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2203). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02352249)
Source record
DIN 02352249: Ran-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id RAN
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2203; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352249
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83748
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Vasotec · DIN 00708879 · $0.2203
Shortage status: resolved shortage (ended May 20, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352249
Shortage record checked October 6, 2026
Vasotec · DIN 00708879 · 5 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: RxHelp ONE lists Vasotec (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Vasotec · DIN 00708879
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Daily cost (source): $1.2182
Health Canada: Marketed since 2022-04-11 · brand VASOTEC · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 4 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00708879)
Source record
DIN 00708879: Vasotec
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800105; group id 322; item number 0716; lccId None; manufacturer id OCI
Source form: Tab; strength: 5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.2182; ministry $0.2203
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00708879
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8111
Therapeutic Notes (formulary)
** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019884 · $0.2203
Co Enalapril · DIN 02291886 · $0.2203
Enalapril · DIN 02400669 · $0.2203
Enalapril · DIN 02442965 · $0.2203
Jamp-Enalapril · DIN 02474794 · $0.2203
Mar-Enalapril · DIN 02459469 · $0.2203
Mylan-Enalapril · DIN 02300044 · $0.2203
Ran-Enalapril · DIN 02352249 · $0.2203
Ratio-Enalapril · DIN 02299992 · $0.2203
Sandoz Enalapril · DIN 02299941 · $0.2203
Taro-Enalapril · DIN 02300125 · $0.2203
Teva-Enalapril · DIN 02233005 · $0.2203
Shortage status: active shortage (reported June 25, 2026, estimated to end October 9, 2026, last updated June 26, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00708879
Shortage record checked October 6, 2026
Apo-Enalapril · DIN 02019892 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Enalapril · DIN 02019892
Manufacturer: Apotex Inc.; listing date 2007-12-19
Daily cost (source): $0.2647
Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Enalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02019892)
Source record
DIN 02019892: Apo-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02019892
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14387
Interchangeable products
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended June 28, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02019892
Shortage record checked October 6, 2026
Co Enalapril · DIN 02291894 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Co Enalapril · DIN 02291894
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-12-19
Daily cost (source): $0.2647
Health Canada: Marketed since 2017-08-18 · brand ACT ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Enalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02291894)
Source record
DIN 02291894: Co Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id COB
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02291894
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77726
Therapeutic Notes (formulary)
** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: discontinued (April 7, 2017, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02291894
Shortage record checked October 6, 2026
Enalapril · DIN 02400677 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Enalapril · DIN 02400677
Manufacturer: Sanis Health Inc.; listing date 2022-02-28
Daily cost (source): $0.2647
Health Canada: Marketed since 2022-01-07 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEnalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02400677)
Source record
DIN 02400677: Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02400677
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88545
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended January 7, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02400677
Shortage record checked October 6, 2026
Enalapril · DIN 02442973 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Enalapril · DIN 02442973
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-11-30
Daily cost (source): $0.2647
Health Canada: Marketed since 2018-10-04 · brand ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordEnalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02442973)
Source record
DIN 02442973: Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442973
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92750
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended October 19, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442973
Shortage record checked October 6, 2026
Jamp-Enalapril · DIN 02474808 · 10 mg · tablet
General benefitMarketed · checked November 19, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Enalapril · DIN 02474808
Manufacturer: Jamp Pharma Corporation; listing date 2019-04-30
Daily cost (source): $0.2647
Health Canada: Marketed since 2019-02-25 · brand JAMP ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp-Enalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474808)
Source record
DIN 02474808: Jamp-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474808
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96499
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended March 18, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474808
Shortage record checked October 6, 2026
Mar-Enalapril · DIN 02444771 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Enalapril · DIN 02444771
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-06-28
Daily cost (source): $0.2647
Health Canada: Marketed since 2019-03-20 · brand MAR-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Enalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444771)
Source record
DIN 02444771: Mar-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444771
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92998
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444771
Shortage record checked October 6, 2026
Ran-Enalapril · DIN 02352257 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Ran-Enalapril · DIN 02352257
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-01-07
Daily cost (source): $0.2647
Health Canada: Marketed since 2022-02-15 · brand TARO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM 8 MG · company Sun pharma canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordRan-Enalapril: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2647). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02352257)
Source record
DIN 02352257: Ran-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id RAN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2647; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02352257
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83749
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Vasotec · DIN 00670901 · $0.2647
Shortage status: resolved shortage (ended November 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352257
Shortage record checked October 6, 2026
Vasotec · DIN 00670901 · 10 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Savings card: RxHelp ONE lists Vasotec (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Vasotec · DIN 00670901
Manufacturer: Organon Canada Inc.; listing date 1996-10-01
Daily cost (source): $1.4638
Health Canada: Marketed since 2022-04-07 · brand VASOTEC · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL SODIUM (ENALAPRIL MALEATE) 8 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00670901)
Source record
DIN 00670901: Vasotec
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800104; group id 322; item number 0717; lccId None; manufacturer id OCI
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.4638; ministry $0.2647
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00670901
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8102
Therapeutic Notes (formulary)
** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.
Interchangeable products
Apo-Enalapril · DIN 02019892 · $0.2647
Co Enalapril · DIN 02291894 · $0.2647
Enalapril · DIN 02400677 · $0.2647
Enalapril · DIN 02442973 · $0.2647
Jamp-Enalapril · DIN 02474808 · $0.2647
Mar-Enalapril · DIN 02444771 · $0.2647
Mylan-Enalapril · DIN 02300052 · $0.2647
Ran-Enalapril · DIN 02352257 · $0.2647
Ratio-Enalapril · DIN 02300001 · $0.2647
Sandoz Enalapril · DIN 02299968 · $0.2647
Taro-Enalapril · DIN 02300133 · $0.2647
Teva-Enalapril · DIN 02233006 · $0.2647
Shortage status: resolved shortage (ended September 12, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00670901
Shortage record checked October 6, 2026
Apo-Enalapril · DIN 02019906 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Enalapril · DIN 02019906
Manufacturer: Apotex Inc.; listing date 2007-12-19
Daily cost (source): $0.3195
Health Canada: Marketed since 1993-12-31 · brand APO-ENALAPRIL · ATC C09AA02 ENALAPRIL · form Tablet · route Oral · ingredients ENALAPRIL MALEATE 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Enalapril: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3195). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02019906)
Source record
DIN 02019906: Apo-Enalapril
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800103; group id 322; item number 0718; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3195; ministry $0.3195
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02019906
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14388
Interchangeable products
Co Enalapril · DIN 02291908 · $0.3195
Enalapril · DIN 02400685 · $0.3195
Enalapril · DIN 02442981 · $0.3195
Jamp-Enalapril · DIN 02474816 · $0.3195
Mar-Enalapril · DIN 02444798 · $0.3195
Mylan-Enalapril · DIN 02300060 · $0.3195
Ran-Enalapril · DIN 02352265 · $0.3195
Ratio-Enalapril · DIN 02300028 · $0.3195
Sandoz Enalapril · DIN 02299976 · $0.3195
Taro-Enalapril · DIN 02300141 · $0.3195
Teva-Enalapril · DIN 02233007 · $0.3195
Vasotec · DIN 00670928 · $0.3195
Shortage status: resolved shortage (ended December 21, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02019906
Shortage record checked October 6, 2026
Other products in the same Health Canada class (C09AA): coverage varies; not interchangeable
- Benazepril (Lotensin): general benefit, not a benefit
- Captopril (Noyada): general benefit, limited Use 707, 723, not a benefit
- Cilazapril (Inhibace): general benefit, not a benefit
- Fosinopril (Monopril): general benefit, not a benefit
- Lisinopril (Prinivil): general benefit, not a benefit
- Perindopril erbumine (Coversyl): general benefit
3 more in the class list below
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab
· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab
· 48 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab
· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab
· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap
· 26 products · Off-Formulary Interchangeable, not an ODB benefit (4), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (18), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:08
and 34 more
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hypertension, or renovascular hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monograph
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (46)
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monograph
BENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for:
• the treatment of essential hypertension in patients for whom combination therapy is
appropriate.
PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10
Product monograph
CAPTOPRIL · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8)
INDICATIONS AND CLINICAL USE
Hypertension
APO-CAPTO (captopril) is indicated for the treatment of essential or renovascular hypertension.
PM: https://pdf.hres.ca/dpd_pm/00022606.PDF; date November 1, 2013; DIN 00893595; fetched 2026-09-10
Product monograph
CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monograph
CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monograph
CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monograph
and 21 more
Coverage source: ON formulary extract 2026-09-22